Saturday 17 October 2026
Export OWLT’s income statement to Excel — free account
Owlet, Inc.
OWLT Healthcare Medical Devices
In the quarter to June 2026, revenue grew 29.9%, EPS grew 97.9%, free cash flow grew 55.7% and total debt fell 16.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.14
0.30
−6.76%
Follow OWLT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.42 | 1.32 | 2.77 | 1.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1,779.03) | (27.91) | (648.10) | (63.22) | |
P/B ratio |
7.07 | 6.71 | 15.38 | 0.00 | |
Price to Tangible BV |
7.75 | 7.32 | 16.60 | 0.00 | |
EV/Sales |
1.27 | 1.11 | 2.51 | 1.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.82) | (11.97) | (24.55) | (18.83) | |
EV/FCF |
(14.82) | (10.63) | (22.58) | (17.34) | |
Quick Ratio |
1.29 | 1.26 | 1.45 | 0.84 | |
Current Ratio |
1.64 | 1.71 | 1.85 | 1.14 | |
Net Debt/EBITDA |
(8.52) | 4.51 | 6.20 | 0.47 | |
Debt/Assets |
18.24% | 21.63% | 15.22% | 33.32% | |
Debt/Equity |
0.46 | 0.55 | 0.42 | (0.58) | |
Asset Turnover |
1.46 | 1.55 | 1.56 | 1.52 | |
Operating CF/Net income |
0.06 | 1.22 | 0.05 | (0.81) | |
Capex/Depreciation |
(1.72) | (0.75) | (0.80) | (0.37) | |
Interest Coverage |
2.46 | (8.04) | (8.71) | 1.41 | |
Research and Development Expense of Revenue |
13.47% | 17.62% | 13.78% | 11.83% | |
Selling, General and Administrative Expense of Revenue |
45.83% | 61.34% | 53.07% | 35.01% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
9.55% | 15.54% | 18.20% | 4.32% | |
Graham Net Nets |
0.19 | 0.21 | 0.09 | (0.34) | |
Graham Number |
0.00 | 0.00 | 0.00 | 14.30 | |
Earnings Yield |
(7.32%) | (53.31%) | (15.32%) | (32.11%) | |
Free Cash Flow Yield |
(6.03%) | (7.92%) | (4.01%) | (5.80%) | |
Revenue per Share |
1.19 | 0.82 | 1.47 | 1.97 | |
Operating CF per Share |
0.00 | (0.18) | (0.02) | (0.13) | |
Capex per Share |
(0.03) | (0.02) | (0.03) | (0.02) | |
Free Cash Flow per Share |
(0.04) | (0.20) | (0.05) | (0.15) | |
Cash per Share |
1.28 | 1.50 | 2.27 | 1.49 | |
Shareholders Equity per Share |
1.29 | 1.23 | 1.72 | (2.65) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.29 | 1.23 | 1.72 | (2.65) | |
Free Cash Flow |
(1.03) | (5.46) | (0.94) | (2.42) | |
Working Capital |
34.48 | 34.31 | 37.67 | 8.70 | |
Capital Expenditures |
(0.94) | (0.41) | (0.49) | (0.25) | |
Net Current Asset Value |
31.58 | 29.55 | 27.32 | (46.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
28.75 | 18.19 | 17.53 | 22.87 | |
Average Payables |
12.52 | 12.24 | 11.62 | 14.59 | |
Average Inventory |
13.52 | 15.00 | 12.91 | 12.56 | |
Average Assets |
78.56 | 69.08 | 67.57 | 65.50 | |
Average Common Equity |
(18.01) | (2.40) | (5.35) | (37.80) |
Columns are period end dates